Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Difluprednate

FDA-approved product (emulsion, ophthalmic), marketed as Difluprednate, Durezol.

Registered studies
25
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Difluprednate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anterior uveitis
  • Eye inflammation
  • Inflammation

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii); Corticosteroids, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

25registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Difluprednate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Difluprednate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

    NCT06765980 · start 2025-05-28

    Registered record
    Registry ID
    NCT06765980
    Conditions
    Geographic Atrophy Secondary to Age-related Macular Degeneration
    Interventions
    VV-14295
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-05-28
    Completion
    2027-12-15
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeographic Atrophy Secondary to Age-related Macular Degeneration
    InterventionVV-14295
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II

    NCT06271772 · start 2024-07-01

    Registered record
    Registry ID
    NCT06271772
    Conditions
    Bacterial Keratitis
    Interventions
    Difluprednate Ophthalmic; Rose Bengal; Moxifloxacin Ophthalmic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-07-01
    Completion
    2027-02-28
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Keratitis
    InterventionDifluprednate Ophthalmic; Rose Bengal; Moxifloxacin Ophthalmic
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of the Effect of Different Doses of Difluprednate Eye Drops on the Intraocular Pressure After Phacoemulsification

    NCT05649111 · start 2022-11-01

    Registered record
    Registry ID
    NCT05649111
    Conditions
    Uveitis, Anterior
    Interventions
    Difluprednate Eye Drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-11-01
    Completion
    2023-02-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveitis, Anterior
    InterventionDifluprednate Eye Drops
    PhasePhase 4
    Registry statusUnknown

  • Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

    NCT04687800 · start 2020-12-01

    Registered record
    Registry ID
    NCT04687800
    Conditions
    Cataract
    Interventions
    Dextenza 0.4mg intracanalicular Insert; Durezol 0.05% Ophthalmic Emulsion
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2020-12-01
    Completion
    2022-10-24
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionDextenza 0.4mg intracanalicular Insert; Durezol 0.05% Ophthalmic Emulsion
    PhasePhase 4
    Registry statusTerminated

  • Steroids and Cross-linking for Ulcer Treatment

    NCT04097730 · start 2020-09-24

    Registered record
    Registry ID
    NCT04097730
    Conditions
    Keratitis Bacterial
    Interventions
    Moxifloxacin Ophthalmic; Difluprednate Ophthalmic; Riboflavin Ophthalmic; Topical Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-24
    Completion
    2024-09-18
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratitis Bacterial
    InterventionMoxifloxacin Ophthalmic; Difluprednate Ophthalmic; Riboflavin Ophthalmic; Topical Placebo
    PhasePhase 3
    Registry statusCompleted

  • Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

    NCT03626376 · start 2019-12-10

    Registered record
    Registry ID
    NCT03626376
    Conditions
    Herpes Simplex Virus Keratitis
    Interventions
    oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily; oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2019-12-10
    Completion
    2022-03-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Simplex Virus Keratitis
    Interventionoral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily; oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
    PhasePhase 4
    Registry statusWithdrawn

  • Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery.

    NCT04631315 · start 2019-03-24

    Registered record
    Registry ID
    NCT04631315
    Conditions
    Cataract
    Interventions
    Difluprednate Ophthalmic Emulsion 0.05%; Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-24
    Completion
    2020-07-21
    Enrolment
    255

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionDifluprednate Ophthalmic Emulsion 0.05%; Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification

    NCT03693989 · start 2018-10-04

    Registered record
    Registry ID
    NCT03693989
    Conditions
    Cataract
    Interventions
    Difluprednate 0.05%; Prednefrin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-10-04
    Completion
    2019-10-22
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionDifluprednate 0.05%; Prednefrin
    PhasePhase 3
    Registry statusCompleted

  • Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

    NCT01939691 · start 2018-09-12

    Registered record
    Registry ID
    NCT01939691
    Conditions
    Uveitis; Macular Edema
    Interventions
    Difluprednate; Nepafenac; Prednisolone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-09-12
    Completion
    2020-03-31
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveitis; Macular Edema
    InterventionDifluprednate; Nepafenac; Prednisolone acetate
    PhasePhase 4
    Registry statusTerminated

  • Non Neutralizing Antibodies: Prevalence and Characterization

    NCT01541527 · start 2012-02

    Registered record
    Registry ID
    NCT01541527
    Conditions
    Hemophilia A
    Interventions
    blood test
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2012-02
    Completion
    2013-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemophilia A
    Interventionblood test
    PhaseNot recorded
    Registry statusWithdrawn

  • Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

    NCT01276223 · start 2011-02

    Registered record
    Registry ID
    NCT01276223
    Conditions
    Dry Eye Disease
    Interventions
    Difluprednate 0.05% ophthalmic emulsion; Difluprednate vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-02
    Completion
    2012-01
    Enrolment
    722

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease
    InterventionDifluprednate 0.05% ophthalmic emulsion; Difluprednate vehicle
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis

    NCT01201798 · start 2010-10

    Registered record
    Registry ID
    NCT01201798
    Conditions
    Endogenous Anterior Uveitis
    Interventions
    Difluprednate 0.05% ophthalmic emulsion; Prednisolone acetate 1.0% ophthalmic suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10
    Completion
    2011-08
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndogenous Anterior Uveitis
    InterventionDifluprednate 0.05% ophthalmic emulsion; Prednisolone acetate 1.0% ophthalmic suspension
    PhasePhase 3
    Registry statusCompleted

  • Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery

    NCT01124045 · start 2010-08

    Registered record
    Registry ID
    NCT01124045
    Conditions
    Cataracts; Inflammation
    Interventions
    Difluprednate ophthalmic emulsion, 0.05%; Prednisolone acetate ophthalmic suspension, 1.0%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-04
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataracts; Inflammation
    InterventionDifluprednate ophthalmic emulsion, 0.05%; Prednisolone acetate ophthalmic suspension, 1.0%
    PhasePhase 3
    Registry statusCompleted

  • Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.

    NCT01244334 · start 2009-03

    Registered record
    Registry ID
    NCT01244334
    Conditions
    Cataracts; Corneal Edema; Retinal Structural Change, Deposit and Degeneration; Visual Acuity Reduced Transiently
    Interventions
    Difluprednate ophthalmic emulsion 0.05%; Prednisolone acetate 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-11
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataracts; Corneal Edema; Retinal Structural Change, Deposit and Degeneration; Visual Acuity Reduced Transiently
    InterventionDifluprednate ophthalmic emulsion 0.05%; Prednisolone acetate 1%
    PhasePhase 4
    Registry statusCompleted

  • Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)

    NCT00616993 · start 2008-01

    Registered record
    Registry ID
    NCT00616993
    Conditions
    Inflammation
    Interventions
    Difluprednate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation
    InterventionDifluprednate; Placebo
    PhasePhase 3
    Registry statusCompleted